摘要
目的:探讨多西他赛联合顺铂治疗晚期胸腺癌的疗效。方法:回顾分析2007年1月—2011年11月70例经组织学确诊的晚期胸腺癌患者的临床资料,按不同治疗方法分为两组,观察组(n=35)采用多西他赛联合顺铂治疗,对照组(n=35)采用其他治疗方案。治疗方法两组均为每4周重复1次,至少2个疗程。结果:观察组和对照组治疗有效率分别为48.6%和25.7%,疾病控制率分别为85.7%和74.2%,两组比较差异均有统计学意义(P<0.05);观察组和对照组患者无进展生存期分别为17个月和11个月,总生存期分别为35个月和27个月,两组比较差异均无统计学意义(P>0.05)。多因素比例风险模型(Cox regression model)分析显示,影响70例晚期胸腺癌患者生存的因素为肿瘤分期和治疗方法。结论:多西他赛联合顺铂治疗晚期胸腺癌疗效较好,化疗联合放疗和(或)手术的多学科治疗可延长患者的生存时间。
Objective： To analyze the efficacy of docetaxel combined with cisplatin in advanced thymic carcinoma. Methods： Clinical data of 70 patients with advanced thymic carcinoma confirmed by pathology from Jan 2007 to Nov 2011 was retrospec- tively analyzed. The patients in observation group（n = 35） were treated by docetaxel combined with cisplatin, and the patients in control group（n = 35） were treated by other chemotherapy methods. Four weeks was taken as a cycle , and patients had at least 2 cycles of chemotherapy in both groups. Results： The response rates （RR） in observation group and control group were 48.6 % and 25.7 %, respectively; the disease control rates （DCR） were 85.7 % and 74.2 %, respectively; and there was signifi- cant difference between the two groups（P〈0.05）. The progression free survival（PFS） in observation group and control group were 17 months and 11 months; and the overall survival（OS） were 35 months and 27 months, respectively （P〉0.05）. Multi- variate Cox regression analysis showed that staging and treatment methods were important prognostic factors. Conclusions： Do- cetaxel combined with cisplatin in the treatment of advanced thymic carcinoma has better efficacy than other chemotherapy. The multidisciplinary treatment can prolong survival time of patients with advanced thymic carcinoma.
出处
《中国临床医学》
2012年第6期611-612,共2页
Chinese Journal of Clinical Medicine
关键词
胸腺癌
化疗
预后
Thymic carcinoma Chemotherapy
Prognosis
